[1] FEHER M D, BRAZIER J, SCHAPER N, et al. Patients’ with type 2 diabetes willingness to pay for insulin therapy and clinical outcomes［J］. Bmj Open Diabetes Res Care, 2016, 4(1): e000192.

[2] SCOTTB W, SU J K, GARY K Y, et al. A GIP receptor agonist exhibits β-Cell anti-apoptotic actions in rat models of diabetes resulting in improved β-Cell function and glycemic control［J］. Plos One, 2010, 5(3): e9590.

[3] BAHTIYAR G, GUTTERMAN D, LEBOVITZ H. Heart failure: a major cardiovascular complication of diabetes mellitus［J］. Current Diabetes Reports, 2016,16(11): 116.

[4] FRIDLYAND L E, P HILIPSON L H. Pancreatic beta cell G-protein coupled receptors and second messenger interactions: asystems biology computational analysis［J］. Plos One, 2016, 11(5): e0152869.

[5] BO A. Islet G protein-coupled receptors as potential targets for treatment of type 2 diabetes［J］. Nature Reviews Drug Discovery, 2009, 8(5): 369-385.

[6] 盛灵通, 孔建龙, 秦健, 等. GLP-1及其类似物治疗糖尿病的研究进展［J］. 糖尿病新世界, 2015, 22(2): 22-23.

    SHENG Tongling, KONG Jianlong, QIN Jian, et al. Research progress of GLP-1 and its analogues in the treatment of diabetes mellitus［J］. New World of Diabetes, 2015, 22(2): 22-23.

[7] NIGEL I, PETER R F. New perspectives on exploitation of incretin peptides for the treatment of diabetes and related disorders［J］. World Journal of Diabetes, 2015, 6(15): 1285.

[8] WANG T, MA X, TANG T, et al. The effect of glucose-dependent insulinotropic polypeptide (GIP) variants on visceral fat accumulation in Han Chinese populations［J］. Nutrition & Diabetes, 2017, 7(5): e278.

[9] CARR R D, LARSEN M O, WINZELL M S, et al. Incretin and islet hormonal responses to fat and protein ingestion in healthy men［J］. American Journal of Physiology Endocrinology & Metabolism, 2008, 295(4): E779.

[10] MEIER J J, GALLWITZ B, SIEPMANN N, et al. Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia［J］. Diabetologia, 2003, 46(6): 798-801.

[11] MOHAMMAD S, PATEL R T, BRUNO J, et al. A naturally occurring GIP receptor variant undergoes enhanced agonist-induced desensitization, which impairs GIP control of adipose insulin sensitivity［J］. Molecular & Cellular Biology, 2014, 34(19): 3618-3629.

[12] PENG W, FIASCHITAESCH N M, VASAVADA R C, et al. Diabetes mellitus［mdash］advances and challenges in human ［beta］-cell proliferation［J］. Nature Reviews Endocrinology, 2015, 11(4): 201.

[13] KAHN S E, COOPERM E, DELP S. Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future［J］. Lancet, 2014, 383(9922): 1068.

[14] CALANNA S, CHRISTENSEN M, HOLST J J, et al. Secretion of glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes: systematic review and meta-analysis of clinical studies［J］. Diabetes Care, 2013, 36(10): 3346.

[15] 谢洁琼, 吕秋军, 温利青, 等. 基于报告基因和PPARγ信号通路的药物筛选模型的建立［J］. 中国药理学通报, 2005, 21(4): 504-507.

    XIE Jieqiong, LU Qiujun, WEN Liqing, et al. Development of drug screening modelbased on reporter gene and the signal transduction of PPARγ［J］. Chinese Pharmacological Bulletin,2005,21(4): 504-507.

[16] 黎思彤, 郑雪萍, 杨学敏, 等. 以 GLP-1受体为靶点的药物筛选模型的建立及功能鉴定［J］. 中国药理学通报, 2017, 33(2): 285-289.

    LI Sitong, ZHENG Xueping, YANG Xuemin, et al. Development and evaluation of a cell model targeted on GLP-1 receptor［J］. Chinese Pharmacological Bulletin, 2017, 33(2): 285-289.

[17] 曾璐漫. GLP1受体激动剂类药物筛选模型的构建［D］. 湖南农业大学, 2015.

    ZENG Luman. Construct the drug screening model for GLP-1 receptor agonists［D］. Hunan Agricultural University, 2015.

[18] 谢洁琼. 抗糖尿病药物筛选模型的建立及应用［D］. 中国人民解放军军事医学科学院, 解放军军事医学科学院, 2005.

    XIE Jieqiong. The development and application of the methods of scerening for the anti-diabetie drugs［D］. Academy of Military Medical Sciences, 2015.

[19] MARTIN C M, IWIN N, FLATTP R, et al. A novel acylated form of (d-Ala(2))GIP with improved antidiabetic potential, lacking effect on body fat stores［J］. Biochimica et Biophysica Acta, 2013, 1830(6): 3407.

[20] ZHANG X, KIM K M. Multifactorial regulation of G protein-coupled receptor endocytosis［J］. Biomolecules & Therapeutics, 2017, 25(1): 26.

[21] TEITLER M, KLEIN M T. A new approach for studying GPCR dimers: drug-induced inactivation and reactivation to reveal GPCR dimer function in vitro, in primary culture, and in vivo［J］. Pharmacol Ther, 2012, 133(2): 205-217.

[22] 李胜, 白波, 陈京. G蛋白偶联受体脱敏內吞和复敏调控机制进展［J］. 济宁医学院学报, 2016, 39(2): 123-127.

    LI Sheng, BAI Bo, CHEN Jing. Regulatoty mechanisms of G protein coupled receptor about desensitization,endocytosis and resensitization［J］. Journal of Jining Medical College, 2016, 39(2): 123-127.

[23] COHEN L J, ESTERHAZY D, KIM S H, et al. Commensal bacteria make GPCR ligands that mimic human signalling molecules［J］. Nature, 2017, 549: 48-53.